These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

993 related articles for article (PubMed ID: 12601523)

  • 21. Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance.
    Foell JL; Diez-Mendiondo BI; Diez OH; Holzer U; Ruck P; Bapat AS; Hoffmann MK; Mittler RS; Dannecker GE
    Immunology; 2004 Sep; 113(1):89-98. PubMed ID: 15312139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus.
    Arribillaga L; Sarobe P; Arina A; Gorraiz M; Borrás-Cuesta F; Ruiz J; Prieto J; Chen L; Melero I; Lasarte JJ
    Vaccine; 2005 May; 23(27):3493-9. PubMed ID: 15855007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
    LaTemple DC; Abrams JT; Zhang SY; Galili U
    Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD137 and CD137 ligand constitutively coexpressed on human T and B leukemia cells signal proliferation and survival.
    Palma C; Binaschi M; Bigioni M; Maggi CA; Goso C
    Int J Cancer; 2004 Jan; 108(3):390-8. PubMed ID: 14648705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD137-mediated immunotherapy for allergic asthma.
    Polte T; Foell J; Werner C; Hoymann HG; Braun A; Burdach S; Mittler RS; Hansen G
    J Clin Invest; 2006 Apr; 116(4):1025-36. PubMed ID: 16528411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice.
    Sabel MS; Conway TF; Chen FA; Bankert RB
    J Immunother; 2000; 23(3):362-8. PubMed ID: 10838665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb.
    Murillo O; Dubrot J; Palazón A; Arina A; Azpilikueta A; Alfaro C; Solano S; Ochoa MC; Berasain C; Gabari I; Pérez-Gracia JL; Berraondo P; Hervás-Stubbs S; Melero I
    Eur J Immunol; 2009 Sep; 39(9):2424-36. PubMed ID: 19662633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice.
    Foell J; Strahotin S; O'Neil SP; McCausland MM; Suwyn C; Haber M; Chander PN; Bapat AS; Yan XJ; Chiorazzi N; Hoffmann MK; Mittler RS
    J Clin Invest; 2003 May; 111(10):1505-18. PubMed ID: 12750400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD137-mediated T cell co-stimulation terminates existing autoimmune disease in SLE-prone NZB/NZW F1 mice.
    Foell J; McCausland M; Burch J; Corriazzi N; Yan XJ; Suwyn C; O'Neil SP; Hoffmann MK; Mittler RS
    Ann N Y Acad Sci; 2003 Apr; 987():230-5. PubMed ID: 12727643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy.
    McMillin DW; Hewes B; Gangadharan B; Archer DR; Mittler RS; Spencer HT
    Hum Gene Ther; 2006 Aug; 17(8):798-806. PubMed ID: 16942440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy.
    Boczkowski D; Lee J; Pruitt S; Nair S
    Cancer Gene Ther; 2009 Dec; 16(12):900-11. PubMed ID: 19498460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule.
    Johnson TS; Mahnke K; Storn V; Schönfeld K; Ring S; Nettelbeck DM; Haisma HJ; Le Gall F; Kontermann RE; Enk AH
    Clin Cancer Res; 2008 Dec; 14(24):8169-77. PubMed ID: 19088032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.
    Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B
    Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.
    Taraban VY; Rowley TF; O'Brien L; Chan HT; Haswell LE; Green MH; Tutt AL; Glennie MJ; Al-Shamkhani A
    Eur J Immunol; 2002 Dec; 32(12):3617-27. PubMed ID: 12516549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of TGFbeta1 makes nonimmunogenic tumor cells effective for therapeutic vaccination.
    Liu P; Jaffar J; Zhou Y; Yang Y; Hellström I; Hellström KE
    J Immunother; 2009 Apr; 32(3):232-9. PubMed ID: 19242377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma.
    Murillo O; Arina A; Hervas-Stubbs S; Gupta A; McCluskey B; Dubrot J; Palazón A; Azpilikueta A; Ochoa MC; Alfaro C; Solano S; Pérez-Gracia JL; Oyajobi BO; Melero I
    Clin Cancer Res; 2008 Nov; 14(21):6895-906. PubMed ID: 18980984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy targeting 4-1BB and its ligand.
    Vinay DS; Kwon BS
    Int J Hematol; 2006 Jan; 83(1):23-8. PubMed ID: 16443548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The therapeutic potential of 4-1BB (CD137) in cancer.
    Nam KO; Kang WJ; Kwon BS; Kim SJ; Lee HW
    Curr Cancer Drug Targets; 2005 Aug; 5(5):357-63. PubMed ID: 16101383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.